Anika Therapeutics (ANIK) Non-Current Assets (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Non-Current Assets of $84.3 million for Q2 2026, down 4.62% year-over-year from $88.4 million in Q2 2025, and down 1.8% quarter-over-quarter from $85.8 million in Q1 2026.
Anika Therapeutics (ANIK) Non-Current Assets (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Non-Current Assets for 17 consecutive years, with $84.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets fell 4.62% year-over-year to $84.3 million; the TTM figure through Jun 2026 stood at $344.9 million (down 4.43% YoY), while the FY2025 annual figure was $86.9 million, down 2.44% from the prior year.
- Non-Current Assets retreated to $84.3 million in Q2 2026 per ANIK's latest filing, from $85.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $186.3 million in Q2 2022 and bottomed at $84.3 million in Q2 2026.
- Historically, Non-Current Assets has averaged $126.4 million across 5 years, with a median of $106.1 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Assets grew 1.03% — and 2024, when it slumped 44.39%.
- Anika Therapeutics' Non-Current Assets stood at $179.6 million in 2022, then plunged by 40.24% to $107.3 million in 2023, then slipped by 16.99% to $89.1 million in 2024, then decreased by 2.44% to $86.9 million in 2025, then slipped by 3.02% to $84.3 million in 2026.
- Business Quant data shows ANIK's Non-Current Assets at $84.3 million in Q2 2026, $85.8 million in Q1 2026, and $86.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Anika Therapeutics | 285.26 Mn | 246.85 Mn | 21.24 Mn | 84.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.28 Mn |
| Mar 31, 2026 | 85.83 Mn |
| Dec 31, 2025 | 86.91 Mn |
| Sep 30, 2025 | 87.85 Mn |
| Jun 30, 2025 | 88.37 Mn |
| Mar 31, 2025 | 88.10 Mn |
| Dec 31, 2024 | 89.09 Mn |
| Sep 30, 2024 | 95.30 Mn |
| Jun 30, 2024 | 107.66 Mn |
| Mar 31, 2024 | 104.78 Mn |
| Dec 31, 2023 | 107.32 Mn |
| Sep 30, 2023 | 171.38 Mn |
| Jun 30, 2023 | 176.68 Mn |
| Mar 31, 2023 | 178.74 Mn |
| Dec 31, 2022 | 179.58 Mn |
| Sep 30, 2022 | 179.99 Mn |
| Jun 30, 2022 | 186.27 Mn |
| Mar 31, 2022 | 176.92 Mn |
| Dec 31, 2021 | 179.01 Mn |
| Sep 30, 2021 | 187.15 Mn |